Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCHERING LABS RECALL OF TRILAFON CONCENTRATE WAS NOT REPORTED

Executive Summary

SCHERING LABS RECALL OF TRILAFON CONCENTRATE WAS NOT REPORTED to FDA, the agency maintained in a regulatory letter issued to the firm Aug. 23. The reg letter cites several adverse GMP findings from an inspection, completed in May, of the firm's Kenilworth, N.J. plant. The inspection was initiated in April when FDA learned of the Schering product removal action from an outside source. The FDA investigators reported confirming that Schering had "recalled" all lots of Trilafon (perphenazine) Concentrate in early April "because of instability and failure to comply with specifications prior to the five-year expiration data" without "procedures for agency notification." The regulatory letter also pointed to the April-May inspection findings that Schering had not reported a dissolution problem found in a lot of Proventil Repetabs. The FDA findings led to Schering's recall of the Proventil (albuterol) lot in July [EDITOR's NOTE: The recall is listed in the Sept. 5 "Enforcement Report" in this issue of "The Pink Sheet," T&G-14]. The FDA inspection team reported that Schering's procedures had allowed for the release of three pans of the Proventil batch even though a fourth pan from the batch, "coated at the same time, by the same person with the same solution" had been found to fail dissolution. FDA also asserted in the regulatory letter that Schering's records of problem investigations, including the Trilafon and Proventil cases, were not adequate. For instance, the FDA-483 adverse findings report on the April-May inspection states that Schering's report of the investigation into the Trilafon instability problem "was incomplete and failed to address sulfoxide release specifications, oxygen content, and other degradation products." Other inspection findings cited in the August 23 regulatory letter included lack of environmental and/or microbiological control over manufacturing areas for bulk drug substances and lack of validation of cleaning procedures in these areas. FDA also pointed out in the letter that Schering had released a batch of Vancenase (beclomethasone) Inhalers containing mold contamination. FDA acknowledged in the letter that Schering has "initiated steps to correct the deficiencies cited." The firm, in turn, noted that a detailed response to the regulatory letter was submitted to FDA during the week of Sept. 3, and it anticipates that "all" related issues will be resolved "within a short period of time."
UsernamePublicRestriction

Register

PS018044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel